Anthropometric data | | | | | | |
Subjects | 20 | 32 | | 13 | 20 | |
Age¶ years | 41.8±6.7 | 55.8±6.2 | <0.001 | 42.0±6.7 | 53.8±6.6 | <0.001 |
Sex (females/males) | 11/9 | 10/22 | 0.40 | 7/6 | 4/10 | 0.80 |
BMI+ kg·m−2 | 22.7±2.9 | 24.4±6.1 | 0.25 | 23.3±3.8 | 25.1±5.3 | 0.30 |
Current smokers | 5 | 7 | 0.90 | 3 | 8 | 0.70 |
Never smokers | 7 | 0 | 0.008 | 5 | 0 | 0.04 |
Former smokers | 8 | 25 | 0.26 | 5 | 16 | 0.40 |
Time of quitting years | 3.5±2.2 | 2.5±1.2 | 0.04 | 2.8±1.2 | 2.1±1.1 | 0.53 |
Smoking history pack-years | 19.5±2.1 | 39.0±15.1 | <0.001 | 14.1±1.9 | 37± 12 | <0.001 |
Lung function | | | | | | |
Pre-BD FEV1 % pred | 77.3±13.8 | 69.8±7.0 | 0.027 | 76.1±10.1 | 69.2±7.3 | 0.027 |
Pre-BD FVC % pred | 91.2±9.9 | 85.1±9.0 | 0.015 | 90.1±9.8 | 88.6±9.0 | 0.54 |
Post-BD FEV1 % pred | 87.7±9.8 | 71.3±7.7 | <0.001 | 89.1±8.2 | 72.2±7.8 | <0.001 |
Post-BD FVC % pred | 96.2±10.9 | 87.4±8.1 | 0.002 | 97.1±7.8 | 90.0±7.2 | 0.01 |
Pre-BD FEV1/FVC ratio | 0.69±0.07 | 0.65±0.04 | <0.001 | 0.70±0.06 | 0.64±0.04 | <0.001 |
Post-BD FEV1/FVC ratio | | 0.65±0.04 | | | 0.65±0.04 | |
Methacholine μg | 125±26; n=7 | | | 149±40; n=4 | | |
Atopy | | | | | | |
Yes/no | 16/4 | 4/28 | 0.004 | 10/3 | 3/21 | 0.04 |
Treatment ongoing | | | | | | |
No treatment | 7 | 4 | | 5 | 2 | |
Short acting β2-agonist | 11 | 13 | | 5 | 10 | |
Long-acting β2-agonists | 2 | 7 | | 3 | 7 | |
Long-acting antimuscarinic antagonist | 0 | 8 | | 0 | 5 | |
Antihypertensive drugs | 8 | 21 | | 3 | 17 | |
Statins | 1 | 5 | | 1 | 8 | |